secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unity Biotechnology, Inc. (—)
CIK:        0001463361
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0000950170-25-035924
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UNITY appoints Bausch + Lomb R&D chief Yehia Hashad to board; advances UBX1325
------------------------------------------------------------------------------

- Dr. Yehia Hashad, EVP R&D and CMO at Bausch + Lomb, joins board effective March 8, 2025.
- Hashad also appointed to Science Committee; receives 20,000-share option grant (3-yr vest) + $45k annual cash retainer.
- CEO cites Hashad's expertise as UNITY prepares for Phase 2b ASPIRE 24-week data readout for UBX1325 in DME.
- Hashad brings 25+ years in ophthalmology and retinal drug development, including leadership at Allergan and Novartis.
- Board chairman notes Hashad's strategic perspective will help advance UBX1325 and pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1463361/000095017025035924/0000950170-25-035924-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1463361/000095017025035924/ubx-20250308.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-035924

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer